These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1014109)

  • 1. Acquired resistance to rifampicin by Mycobacterium kansasii.
    Davidson PT; Waggoner R
    Tubercle; 1976 Dec; 57(4):271-3. PubMed ID: 1014109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro susceptibility of atypical mycobacteria to rifampin.
    Molavi A; Weinstein L
    Appl Microbiol; 1971 Jul; 22(1):23-5. PubMed ID: 5111305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chemotherapeutic regimens for nontuberculous mycobacterial infection based on in-vitro susceptibility test results].
    Tsukamura M; Yamori S
    Kekkaku; 1990 May; 65(5):349-57. PubMed ID: 2168003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of rifampicin on Mycobacterium ulcerans.
    Havel A; Pattyn SR
    Ann Soc Belg Med Trop; 1975; 55(2):105-8. PubMed ID: 1164050
    [No Abstract]   [Full Text] [Related]  

  • 5. Susceptibility of Runyon Group I Mycobacteria to rifampicin.
    Saito H; Yamamoto S; Yamura T
    Hiroshima J Med Sci; 1972 Mar; 21(1):35-40. PubMed ID: 4661749
    [No Abstract]   [Full Text] [Related]  

  • 6. Mycobacterium fortuitum infections: a review with two illustrative cases.
    Halpern AA; Nagel DA
    Clin Orthop Relat Res; 1978 Oct; (136):247-52. PubMed ID: 729293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Combination of gentamycin and amikacin with rifampicin, ethambutol and isoniazid on selected standard strains of Mycobacterium species in experiments done in vitro and in vivo].
    Janowiec M; Andrzejczyk Z; Marczewska J
    Pneumonol Pol; 1989 May; 57(5):300-7. PubMed ID: 2633149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo studies of the action of rifampicin, clofazimine and B1912 on Mycobacterium marinum.
    Banerjee DK; Holmes IB
    Chemotherapy; 1976; 22(3-4):242-52. PubMed ID: 1269290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-course chemotherapy for mycobacteriosis kansasii?
    Schraufnagel DE; Leech JA; Schraufnagel MN; Pollak B
    Can Med Assoc J; 1984 Jan; 130(1):34-8. PubMed ID: 6418368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibility of mycobacteria to rifampin.
    Woodley CL; Kilburn JO; David HL; Silcox VA
    Antimicrob Agents Chemother; 1972 Oct; 2(4):245-9. PubMed ID: 4670494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Acquired rifampicin resistance during M. kansasii infection in a patient with AIDS].
    Dautzenberg B; Antoun F; Truffot C
    Rev Mal Respir; 1992; 9(4):464-6. PubMed ID: 1509191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Synergistic effects of davercin, rifampicin, ethambutol and isonicotinic acid hydrazide on selected standard strains of Mycobacterium in the in-vitro and in-vivo experiments].
    Janowiec M; Andrzejczyk Z; Szwedowicz I
    Pneumonol Pol; 1988 Jun; 56(6):278-82. PubMed ID: 3226945
    [No Abstract]   [Full Text] [Related]  

  • 13. Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol. Research Committee, British Thoracic Society.
    Thorax; 1994 May; 49(5):442-5. PubMed ID: 8016763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Detection of rpoB mutations in rifampicin-resistant Mycobacterium kansasii].
    Yoshida S; Suzuki K; Tsuyuguchi K; Iwamoto T; Tomita M; Okada M; Sakatani M
    Kekkaku; 2006 Jul; 81(7):475-9. PubMed ID: 16910599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary infection with Mycobacterium kansasii in Wales, 1970-9: review of treatment and response.
    Banks J; Hunter AM; Campbell IA; Jenkins PA; Smith AP
    Thorax; 1983 Apr; 38(4):271-4. PubMed ID: 6867979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rifampin resistance in Mycobacterium kansasii is associated with rpoB mutations.
    Klein JL; Brown TJ; French GL
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3056-8. PubMed ID: 11600355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rifampin alone and combined with other drugs in Mycobacterium kansasii and Mycobacterium intracellulare infections of mice.
    Shronts JS; Rynearson TK; Wolinsky E
    Am Rev Respir Dis; 1971 Nov; 104(5):728-41. PubMed ID: 5125181
    [No Abstract]   [Full Text] [Related]  

  • 18. Response to chemotherapy of pulmonary infection due to Mycobacterium kansasii.
    Harris GD; Johanson WG; Nicholson DP
    Am Rev Respir Dis; 1975 Jul; 112(1):31-6. PubMed ID: 1147382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A case of Mycobacterium kansasii lung infection developed after treatment of Mycobacterium gordonae lung infection].
    Umeki S; Okamoto Y; Hara Y
    Kekkaku; 1988 Dec; 63(12):785-90. PubMed ID: 3226033
    [No Abstract]   [Full Text] [Related]  

  • 20. Response to chemotherapy of pulmonary infection due to mycobacterium kansasii.
    Harris GD; Johnason WG; Nicholson D
    Bull Int Union Tuberc; 1976; 51(1):275-8. PubMed ID: 1030296
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.